当前位置: X-MOL 学术J. Infect. Dis. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Serial Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography (18FDG-PET-CT) in Assessing Treatment Response in Chronic Pulmonary Aspergillosis
The Journal of Infectious Diseases ( IF 5.0 ) Pub Date : 2024-08-19 , DOI: 10.1093/infdis/jiae409
Inderpaul Singh Sehgal 1 , Kajal Arora 1 , Ritesh Agarwal 1 , Rajender Kumar 2 , Nivedita Rana 2 , Sahajal Dhooria 1 , Valliappan Muthu 1 , Kuruswamy Thurai Prasad 1 , Mandeep Garg 3 , Shivaprakash M Rudramurthy 4 , Ashutosh Nath Aggarwal 1 , Arunaloke Chakrabarti 5
Affiliation  

Background The role of 2-deoxy-2-18(F) fluoro-D-glucose (FDG) positron emission tomography (PET)-computed tomography (CT) in assessing treatment response in chronic pulmonary aspergillosis (CPA) remains to be determined. The study objective was to compare FDG-PET/CT parameters in persons with CPA achieving treatment success or failure after 6 months of oral itraconazole. Methods We performed PET-CT at baseline and after 6 months of oral itraconazole therapy. FDG uptake similar to the background uptake or ≥13 units decline in Z-score was considered a complete metabolic response (CMR). A >25%, >30%, and > 45% decline in standardised uptake value (SUVmax), SUVpeak, and total glycolytic activity (TLG) was labelled as a partial metabolic response (PMR). A >30%, >30%, or >75% increase in the SUVmax, SUVpeak, and TLG represented progressive metabolic disease. Results We included 94 persons with CPA (63 male) with a mean age of 46.2 years. A follow-up PET-CT was performed on 77 participants. We recorded treatment success and failure in 43 and 34 patients. CMR was seen in 18.6% of those with treatment success and none with treatment failure. A higher proportion of patients with treatment success achieved PMR; 19% of the patients with treatment success had progressive metabolic disease. Conclusions Most PET-CT parameters improved with treatment; however, PET-CT misclassified one-fifth of the participants.

中文翻译:


连续氟脱氧葡萄糖正电子发射断层扫描-计算机断层扫描 (18FDG-PET-CT) 评估慢性肺曲霉病的治疗反应



背景 2-脱氧-2-18(F) 氟-D-葡萄糖 (FDG) 正电子发射断层扫描 (PET) -计算机断层扫描 (CT) 在评估慢性肺曲霉病 (CPA) 治疗反应中的作用仍有待确定。研究目的是比较口服伊曲康唑 6 个月后 CPA 患者达到治疗成功或失败的 FDG-PET/CT 参数。方法 我们在基线和口服伊曲康唑治疗 6 个月后进行 PET-CT。FDG 摄取与背景摄取相似或 Z 评分下降 ≥13 单位被认为是完全代谢反应 (CMR)。标准化摄取值 (SUVmax)、SUVpeak 和总糖酵解活性 (TLG) 的 >25%、>30% 和 > 45% 下降被标记为部分代谢反应 (PMR)。SUVmax、SUVpeak 和 TLG 的 >30%、>30% 或 >75% 增加表示进行性代谢性疾病。结果 我们纳入了 94 例 CPA 患者 (63 例男性),平均年龄为 46.2 岁。对 77 名参与者进行了随访 PET-CT。我们记录了 43 例和 34 例患者的治疗成功和失败。18.6% 的治疗成功患者出现 CMR,而治疗失败的患者无 CMR。治疗成功的患者达到 PMR 的比例更高;19% 的治疗成功患者患有进行性代谢性疾病。结论 大多数 PET-CT 参数随着治疗而改善;然而,PET-CT 错误地分类了五分之一的参与者。
更新日期:2024-08-19
down
wechat
bug